Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381:1535–1546.

• PubMed
Larkin J, Chiarion-Sileni V, Gonzalez R, Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381:1535–1546.31562797)| false
• Search Google Scholar
• Export Citation

Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107–114.

• PubMed
Flaherty KT, Robert C, Hersey P, Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107–114.22663011)| false
• Search Google Scholar
• Export Citation

Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 2017;18:863–873.

• PubMed
Davies MA, Saiag P, Robert C, Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 2017;18:863–873.)| false
• Search Google Scholar
• Export Citation

Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016;17:1248–1260.

• PubMed
Ascierto PA, McArthur GA, Dréno B, Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016;17:1248–1260.27480103)| false
• Search Google Scholar
• Export Citation

Grossmann KF, Margolin K. Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol 2015;7:181–191.

• PubMed
Grossmann KF, Margolin K. Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol 2015;7:181–191.26673806)| false
• Search Google Scholar
• Export Citation

Pilié PG, Gay CM, Byers LA, et al. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res 2019;25:3759–3771.

• PubMed
Pilié PG, Gay CM, Byers LA, PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res 2019;25:3759–3771.30760478)| false
• Search Google Scholar
• Export Citation

Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol 2018;2:PO.17.00286.

• PubMed
Heeke AL, Pishvaian MJ, Lynce F, Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol 2018;2:PO.17.00286.)| false
• Search Google Scholar
• Export Citation

Kim H, Ahn S, Kim H, et al. The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. J Cancer Res Clin Oncol 2022;148:2427–2435.

• PubMed
Kim H, Ahn S, Kim H, The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. J Cancer Res Clin Oncol 2022;148:2427–2435.34510272)| false
• Search Google Scholar
• Export Citation

Plummer R, Lorigan P, Steven N, et al. A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 2013;71:1191–1199.

• PubMed
Plummer R, Lorigan P, Steven N, A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 2013;71:1191–1199.23423489)| false
• Search Google Scholar
• Export Citation

Chan WY, Brown LJ, Reid L, et al. PARP inhibitors in melanoma—an expanding therapeutic option? Cancers (Basel) 2021;13:4520.

• PubMed
Chan WY, Brown LJ, Reid L, PARP inhibitors in melanoma—an expanding therapeutic option? Cancers (Basel) 2021;13:4520.34572747)| false
• Search Google Scholar
• Export Citation

Lau B, Menzies AM, Joshua AM. Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report. Ann Oncol 2021;32:280–282.

• PubMed
Lau B, Menzies AM, Joshua AM. Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report. Ann Oncol 2021;32:280–282.33308898)| false
• Search Google Scholar
• Export Citation

Kiel PJ, Radovich M, Schneider BP, Logan TF. Sustained exceptional response to poly (ADP-ribose) polymerase inhibition plus temozolomide in metastatic melanoma with DNA repair deficiency. JCO Precis Oncol 2018;2:1–7.

• PubMed
Kiel PJ, Radovich M, Schneider BP, Logan TF. Sustained exceptional response to poly (ADP-ribose) polymerase inhibition plus temozolomide in metastatic melanoma with DNA repair deficiency. JCO Precis Oncol 2018;2:1–7.35135169)| false
• Search Google Scholar
• Export Citation

Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012;107:1776–1782.

• PubMed
Abkevich V, Timms KM, Hennessy BT, Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012;107:1776–1782.23047548)| false
• Search Google Scholar
• Export Citation

Birkbak NJ, Wang ZC, Kim JY, et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012;2:366–375.

• PubMed
Birkbak NJ, Wang ZC, Kim JY, Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012;2:366–375.22576213)| false
• Search Google Scholar
• Export Citation

Popova T, Manié E, Rieunier G, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012;72:5454–5462.

• PubMed
Popova T, Manié E, Rieunier G, Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012;72:5454–5462.22933060)| false
• Search Google Scholar
• Export Citation

Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154–2164.

• PubMed
Mirza MR, Monk BJ, Herrstedt J, Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154–2164.27717299)| false
• Search Google Scholar
• Export Citation

Takaya H, Nakai H, Takamatsu S, et al. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Sci Rep 2020;10:2757.

• PubMed
Takaya H, Nakai H, Takamatsu S, Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Sci Rep 2020;10:2757.32066851)| false
• Search Google Scholar
• Export Citation

Khaddour K, Ansstas M, Visconti J, et al. Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade? Ann Oncol 2021;32:279–280.

• PubMed
Khaddour K, Ansstas M, Visconti J, Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade? Ann Oncol 2021;32:279–280.)| false
• Search Google Scholar
• Export Citation

Khaddour K, Ansstas M, Ansstas G. Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency. Cold Spring Harb Mol Case Stud 2021;7:a006129.

• PubMed
Khaddour K, Ansstas M, Ansstas G. Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency. Cold Spring Harb Mol Case Stud 2021;7:a006129.34667064)| false
• Search Google Scholar
• Export Citation

Leibowitz BD, Dougherty BV, Bell JSK, et al. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. BMC Cancer 2022;22:587.

• PubMed
Leibowitz BD, Dougherty BV, Bell JSK, Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. BMC Cancer 2022;22:587.)| false
• Search Google Scholar
• Export Citation

Bell JSK, Venkat A, Parsons J, et al. An integrative molecular framework to predict homologous recombination deficiency. J Clin Oncol 2020;38(Suppl):Abstract e15664.

• PubMed
Bell JSK, Venkat A, Parsons J, An integrative molecular framework to predict homologous recombination deficiency. J Clin Oncol 2020;38(Suppl):Abstract e15664.)| false
• Search Google Scholar
• Export Citation

Tempus. Genetic profiling. Accessed October 29, 2022. Available at: https://www.tempus.com/oncology/genomic-profiling/

• PubMed
Tempus. Genetic profiling. Accessed October 29, 2022. Available at: https://www.tempus.com/oncology/genomic-profiling/)| false
• Search Google Scholar
• Export Citation

Beaubier N, Tell R, Lau D, et al. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget 2019;10:2384–2396.

• PubMed
Beaubier N, Tell R, Lau D, Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget 2019;10:2384–2396.31040929)| false
• Search Google Scholar
• Export Citation

Beaubier N, Bontrager M, Huether R, et al. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol 2019;37:1351–1360.

• PubMed
Beaubier N, Bontrager M, Huether R, Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol 2019;37:1351–1360.31570899)| false
• Search Google Scholar
• Export Citation

Fernandes LE, Epstein CG, Bobe AM, et al. Real-world evidence of diagnostic testing and treatment patterns in US patients with breast cancer with implications for treatment biomarkers from RNA sequencing data. Clin Breast Cancer 2021;21:e340–361.

• PubMed
Fernandes LE, Epstein CG, Bobe AM, Real-world evidence of diagnostic testing and treatment patterns in US patients with breast cancer with implications for treatment biomarkers from RNA sequencing data. Clin Breast Cancer 2021;21:e340–361.33446413)| false
• Search Google Scholar
• Export Citation

Kim KB, Soroceanu L, de Semir D, et al. Prevalence of homologous recombination pathway gene mutations in melanoma: rationale for a new targeted therapeutic approach. J Invest Dermatol 2021;141:2028–2036.e2.

• PubMed
Kim KB, Soroceanu L, de Semir D, Prevalence of homologous recombination pathway gene mutations in melanoma: rationale for a new targeted therapeutic approach. J Invest Dermatol 2021;141:2028–2036.e2.33610559)| false
• Search Google Scholar
• Export Citation

van Wijk LM, Nilas AB, Vrieling H, et al. RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox? Expert Rev Mol Diagn 2022;22:185–199.

• PubMed
van Wijk LM, Nilas AB, Vrieling H, RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox? Expert Rev Mol Diagn 2022;22:185–199.)| false
• Search Google Scholar
• Export Citation

Makino E, Fröhlich LM, Sinnberg T, et al. Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition. Cell Death Dis 2020;11:581.

• PubMed
Makino E, Fröhlich LM, Sinnberg T, Targeting Rad51 as a strategy for the treatment of melanoma cells resistant to MAPK pathway inhibition. Cell Death Dis 2020;11:581.32719412)| false
• Search Google Scholar
• Export Citation

Moschetta M, George A, Kaye SB, et al. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol 2016;27:1449–1455.

• PubMed
Moschetta M, George A, Kaye SB, BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol 2016;27:1449–1455.27037296)| false
• Search Google Scholar
• Export Citation

Sahnane N, Carnevali I, Formenti G, et al. BRCA methylation testing identifies a subset of ovarian carcinomas without germline variants that can benefit from PARP inhibitor. Int J Mol Sci 2020;21:9708.

• PubMed
Sahnane N, Carnevali I, Formenti G, BRCA methylation testing identifies a subset of ovarian carcinomas without germline variants that can benefit from PARP inhibitor. Int J Mol Sci 2020;21:9708.33352687)| false
• Search Google Scholar
• Export Citation

Smeby J, Kryeziu K, Berg KCG, et al. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine 2020;59:102923.

• PubMed
Smeby J, Kryeziu K, Berg KCG, Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine 2020;59:102923.32799124)| false
• Search Google Scholar
• Export Citation

Chabanon RM, Muirhead G, Krastev DB, et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest 2019;129:1211–1228.

• PubMed
Chabanon RM, Muirhead G, Krastev DB, PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest 2019;129:1211–1228.30589644)| false
• Search Google Scholar
• Export Citation

Nolan E, Savas P, Policheni AN, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med 2017;9:eaal4922.

• PubMed
Nolan E, Savas P, Policheni AN, Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med 2017;9:eaal4922.28592566)| false
• Search Google Scholar
• Export Citation

Connor AA, Denroche RE, Jang GH, et al. Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma. JAMA Oncol 2017;3:774–783.

• PubMed
Connor AA, Denroche RE, Jang GH, Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma. JAMA Oncol 2017;3:774–783.27768182)| false
• Search Google Scholar
• Export Citation

Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189–2199.

• PubMed
Snyder A, Makarov V, Merghoub T, Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189–2199.25409260)| false
• Search Google Scholar
• Export Citation

Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017;23:3711–3720.

• PubMed
Jiao S, Xia W, Yamaguchi H, PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017;23:3711–3720.28167507)| false
• Search Google Scholar
• Export Citation

Teo MY, Seier K, Ostrovnaya I, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol 2018;36:1685–1694.

• PubMed
Teo MY, Seier K, Ostrovnaya I, Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol 2018;36:1685–1694.29489427)| false
• Search Google Scholar
• Export Citation

Drew Y, Penson RT, O’Malley DM, et al. Phase II study of olaparib plus durvalumab and bevacizumab (MEDIOLA): initial results in patients with non-germline BRCA-mutated platinum sensitive relapsed ovarian cancer. Ann Oncol 2020;31(Suppl 4):S551–589. Abstract 814MO.

• PubMed
Drew Y, Penson RT, O’Malley DM, Phase II study of olaparib plus durvalumab and bevacizumab (MEDIOLA): initial results in patients with non-germline BRCA-mutated platinum sensitive relapsed ovarian cancer. Ann Oncol 2020;31(Suppl 4):S551–589. Abstract 814MO.)| false
• Search Google Scholar
• Export Citation

Vikas P, Borcherding N, Chennamadhavuni A, et al. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol 2020;10:570.

• PubMed
Vikas P, Borcherding N, Chennamadhavuni A, Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol 2020;10:570.32457830)| false
• Search Google Scholar
• Export Citation